C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
Rhea-AI Summary
C4 Therapeutics (Nasdaq: CCCC) dosed the first patient in the Phase 2 MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for relapsed/refractory multiple myeloma.
The open-label, single-arm study will enroll ~100 patients at the 100 µg dose (14 days on/14 days off dosing) with overall response rate as the primary endpoint. Enrollment is expected to complete in Q1 2027, and a Phase 1b combination trial with elranatamab is on track to initiate in Q2 2026.
Positive
- First patient dosed in Phase 2 MOMENTUM trial
- Trial planned for ~100 patients at 100 µg dose
- Phase 1b combo with elranatamab on track to start Q2 2026
- Oral IKZF1/3 degrader offers potential convenient therapy option
Negative
- Open-label, single-arm design may limit comparative efficacy assessment
- Enrollment completion projected for Q1 2027, creating multi-quarter timeline risk
News Market Reaction – CCCC
On the day this news was published, CCCC gained 6.48%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.6% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $14M to the company's valuation, bringing the market cap to $226M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Among close biotech peers, only SLS appears in momentum scans, up about 2.65% without news, while others show mixed moves. This points to a stock-specific reaction for CCCC.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 01 | Cemsidomide combo deal | Positive | -3.1% | Pfizer collaboration for Phase 1b cemsidomide and elranatamab in RRMM. |
| Nov 06 | CFT8919 trial start | Positive | -2.0% | Partner-dosed first patient in Phase 1 CFT8919 NSCLC trial in China. |
| Sep 13 | CFT1946 Phase 1 data | Positive | +0.5% | Early CFT1946 monotherapy data showing tumor reductions and partial responses. |
| Aug 14 | ESMO upgrade notice | Positive | -0.5% | ESMO upgraded CFT1946 abstract to oral presentation, signaling scientific interest. |
| Apr 08 | CFT1946 preclinical data | Positive | +1.9% | Preclinical CFT1946 data showing superior single-agent activity vs BRAF standards. |
Clinical trial updates for CCCC have often seen muted or negative next-day moves despite generally positive scientific news, with more divergences than alignments to headline tone.
Recent clinical news has focused on multiple assets and combinations. In Apr 2024 and Sep 2024, C4T reported encouraging CFT1946 data and presentations. Later in Nov 2024, a partner-dosed Phase 1 trial for CFT8919 was announced. In Oct 2025, C4T disclosed a cemsidomide–elranatamab collaboration, followed by additional cemsidomide combo plans. These events laid the groundwork for the current Phase 2 MOMENTUM dosing milestone in relapsed/refractory multiple myeloma.
Historical Comparison
Across recent clinical trial updates, CCCC’s average next-day move was -0.66%. Today’s modest +1.89% reaction to the Phase 2 dosing news is somewhat stronger than that pattern.
Clinical news has progressed from preclinical and early CFT1946 data to partner-led CFT8919 trials and a Pfizer-backed cemsidomide combo. The current first-patient dosing in MOMENTUM advances cemsidomide further into Phase 2 in RRMM.
Regulatory & Risk Context
An effective S-3 shelf filed on 2025-11-21 allows C4 Therapeutics to offer up to $400,000,000 of securities, including an at-the-market component of up to $125,000,000, providing flexible capital access for pipeline development.
Market Pulse Summary
The stock moved +6.5% in the session following this news. A strong positive reaction aligns with the clear clinical advancement signaled by first-patient dosing in the Phase 2 MOMENTUM trial and firm timelines into Q2 2026 and Q1 2027. Historically, CCCC’s clinical updates averaged about -0.66% next-day, so a sizable upside move would mark a break from that pattern. Investors have to weigh this enthusiasm against capital flexibility from the $400,000,000 shelf and the early-stage nature of these trials.
Key Terms
relapsed/refractory multiple myeloma medical
pharmacokinetics medical
pharmacodynamics medical
overall response rate medical
International Myeloma Working Group medical
independent review committee technical
B-cell maturation antigen medical
bispecific antibody medical
AI-generated analysis. Not financial advice.
Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027
Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM).
“Initiating the Phase 2 MOMENTUM trial, which builds upon the compelling anti-myeloma activity and differentiated safety profile established in the Phase 1 trial, is a critical step for cemsidomide to become a foundational therapy for multiple myeloma patients, who are in need of a safe, oral, and convenient treatment option,” said Len Reyno, chief medical officer of C4 Therapeutics. “With this milestone accomplished, we are also on track to initiate the Phase 1b trial of cemsidomide in combination with elranatamab in the second quarter, as we continue to advance our regulatory strategy that could deliver two accelerated approval paths in multiple myeloma.”
The Phase 2 MOMENTUM trial is an open-label, single-arm, multicenter study to assess anti-myeloma activity and further characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of cemsidomide, an oral IKZF1/3 degrader, in combination with dexamethasone in RRMM patients for the fourth line or later. The trial will enroll approximately 100 patients to evaluate cemsidomide at the 100 µg dose level. Cemsidomide is administered with a daily dosing schedule of 14 days on and 14 days off, and dexamethasone is dosed once a week. The primary endpoint is the overall response rate per the International Myeloma Working Group response criteria as assessed by an independent review committee. Secondary endpoints will evaluate a range of additional safety and efficacy measures.
The Phase 2 MOMENTUM trial is part of a broader development strategy for cemsidomide, which also includes a Phase 1b study of cemsidomide in combination with elranatamab (ELREXFIO®). Elranatamab is an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. Together, these trials support cemsidomide’s use across multiple lines of treatment.
ANTICIPATED UPCOMING MILESTONES
- Phase 1b trial of cemsidomide in combination with elranatamab is on track to initiate in Q2 2026.
- Further analysis of the completed Phase 1 trial of cemsidomide in combination with dexamethasone is expected in mid-2026.
- Enrollment for Phase 2 MOMENTUM trial is expected to be completed in Q1 2027.
About Cemsidomide
Cemsidomide is an investigational, orally bioavailable molecular glue degrader (MonoDAC® degrader) of IKZF1/3, transcription factors foundational to multiple myeloma biology. Data from the Phase 1 trial, which has completed enrollment, show cemsidomide’s differentiated safety and tolerability profile and potentially class-leading anti-myeloma activity that support the potential for durable outcomes.
About the MOMENTUM Trial
MOMENTUM (Multi-center trial Of cemsidoMidE iN relapsed/refracTory mUltiple Myeloma) is a Phase 2, open-label, single-arm, study to evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Data from the Phase 1 trial identified 100 µg as the recommended Phase 2 dose. The primary endpoint is overall response rate per International Myeloma Working Group response criteria, as assessed by an independent review committee. Approximately 100 patients who have received at least three prior anti-myeloma regimens that must have included an IKZF1/3 degrader, a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager or CAR-T therapy will be enrolled in the trial. More information is available at clinicaltrials.gov (NCT07284758).
About Cemsidomide in Combination With Elranatamab (ELREXFIO®)
The Phase 1b trial is designed to evaluate the safety, tolerability and preliminary efficacy of cemsidomide in combination with elranatamab, an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. The study will evaluate different cemsidomide dose levels (beginning with 75 µg, with the opportunity to simultaneously explore 50 µg and 100 µg) in patients who have received one to four prior lines of therapy, which must have consisted of at least one IKZF1/3 degrader. Exclusion criteria for patients include those who have received prior treatment with a BCMA-directed T-cell engager or BCMA-directed CAR-T therapy. More information is available at clinicaltrials.gov (NCT07280013).
About Multiple Myeloma
Multiple myeloma (MM) is a rare blood cancer affecting plasma cells. Approximately 36,000 people in the United States are diagnosed with MM each year. Approved IKZF1/3 degraders remain foundational therapies across lines of MM treatment. Despite advances, including immune-directed approaches, most patients ultimately relapse, underscoring a growing need for new therapeutics options that continue to leverage IKZF1/3 degradation to drive myeloma cell death and T-cell activation.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Forward Looking Statements
This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC® degraders; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement and patient enrollment; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our ability to replicate interim or early-stage results from our clinical trials in the results obtained when those clinical trials are completed or when those therapies complete later-stage clinical trials; regulatory developments in the United States and foreign countries; the anticipated timing and content of presentations of data from our clinical trials; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.
Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
FAQ
What is the Phase 2 MOMENTUM trial for C4 Therapeutics (CCCC)?
When is enrollment for the C4 Therapeutics (CCCC) Phase 2 MOMENTUM trial expected to finish?
What dosing schedule is C4 Therapeutics using in the MOMENTUM trial (CCCC)?
Will C4 Therapeutics (CCCC) test cemsidomide with other therapies?
What is the primary endpoint of the MOMENTUM trial for C4 Therapeutics (CCCC)?
How might the MOMENTUM trial design affect regulatory review for C4 Therapeutics (CCCC)?
